Cognigenics

Cognigenics is an early-stage biotech pioneering intranasal RNAi delivery for precision neuropsychiatry. Founded in 2020 and based in San Diego, the company's core technology, iRNAi™, is a non-invasive platform intended to silence specific genes in key brain circuits to address the root causes of disorders related to memory and mood. While still in pre-clinical development, the platform represents a potentially disruptive modality for central nervous system (CNS) therapeutics, targeting a significant unmet medical need with a mechanism that promises precision and durability. The company appears to be privately held and pre-revenue, advancing its research through scientific publication and accelerator participation.

iRNAi™: A non-invasive intranasal platform for delivering RNA interference (RNAi) therapeutics directly to the brain to silence specific genes in targeted neural circuits, bypassing the blood-brain barrier.

Cognigenics competes in the crowded CNS therapeutic space against large pharma and biotechs using modalities like small molecules, antibodies, gene therapy, and psychedelics. Its direct competitors are other companies developing RNA-based therapies or novel delivery methods for the brain, though the intranasal RNAi approach appears distinctive.